Navigation Links
Pharmatek Granted Approval by the DEA for Analysis of All Controlled Substances
Date:4/17/2011

SAN DIEGO, April 17, 2011 /PRNewswire/ -- Pharmatek Laboratories, Inc., a premier contract development and manufacturing organization supporting the pharmaceutical industry, announced that it has been approved by the United States Drug Enforcement Agency (DEA) for the analysis of Schedules I through V controlled substances, complementing its existing license to develop and manufacture drug products containing Schedules IV and V controlled substances.

"Receipt of this additional registration from the DEA demonstrates that we meet the Agency's stringent requirements, and further validates our facility design, security systems, and procedures for analysis, handling, storage and disposal of controlled substances," said Jeffrey Bibbs, Ph.D, CEO and CSO at Pharmatek.  "This registration allows us to perform analytical and stability testing for all controlled-substance drug products within both our non-potent and highly-potent GMP facilities."

Controlled substances are designated as Schedule I-V according to their medical use, potential for abuse and safety or dependence liability.  In order to research, manufacture or distribute a controlled substance, a person or entity must be audited and registered by the DEA.

"The DEA registration is another example of our efforts for continuous improvement and expansion of Pharmatek's services," said Timothy Scott, President at Pharmatek.  "As a client-centric organization, our success is predicated on our ability to serve our clients' evolving needs.  We are happy to bring this additional capability to Pharmatek in order to serve that purpose."

About Pharmatek Laboratories, Inc.

Pharmatek Laboratories, Inc. is a premier pharmaceutical chemistry development company providing full-service pharmaceutical chemistry product development for the pharmaceutical industry.  Pharmatek focuses on bringing client compounds from discovery to the clinic with services that include compound selection, analytical development, preformulation testing, formulation development, GMP manufacturing, stability storage and testing, and cytotoxic and high-potency development and manufacturing.

Statements contained in this media release which are not historical facts may constitute forward-looking statements.  All forward-looking statements are subject to risks and uncertainties which could cause actual results to differ from those projected including sales forecasts and strategic expansion.  The trademarks Pharmatek, Pharmatek Laboratories, Inc., Hot Rod Chemistry, Pharmatek Formulation Screening, Pharmatek University and PTEK U are all property of Pharmatek Laboratories, Inc.  Additional information about Pharmatek Laboratories may be obtained at the Web site http://www.pharmatek.com or by calling 858-805-6383.

Company Contact:
Ryan Lane, Marketing Associate
Pharmatek Laboratories, Inc.
(858) 805-6383 x284
rlane@pharmatek.com


'/>"/>
SOURCE Pharmatek Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmatek Laboratories Expands GMP Manufacturing Capabilities
2. Pharmatek Laboratories Announces Acquisition of the First Xcelodose(R) 600S System on the West Coast
3. Pharmateks Highly-Potent and Cytotoxic (HP/C) Facility Positions It as Industry Leader in Development and Manufacturing of HP/C Compounds
4. Exergen Granted New Patent for Temporal Artery Thermometers
5. CardioGenics Granted Patent for Core Technology of its QL Care™ Analyzer
6. Biomerix Granted CE Mark for its REVIVE™ Soft Tissue Repair Mesh
7. Ascension Orthopedics Granted Patent for PyroCarbon Humeral Head Design
8. Dongsheng Pharmaceutical International Co. Granted Exclusive Sales Rights for Thymosin Alpha 1 Injection
9. OrbusNeich Granted Expanded U.S. Patent of Genous™ Endothelial Progenitor Cell Capture Technology
10. S*BIOs JAK2 Inhibitor SB1518 Granted Orphan Drug Designation by European Commission (EC) for the Treatment of Myelofibrosis (MF)
11. Mylan Granted Temporary Restraining Order Against GlaxoSmithKline and Apotex Prohibiting the Supply, Sale and/or Importing of a Generic Version of Paxil CR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , Schweiz, April 27, 2016 ... Sachs CEO Forums in Zürich gab Strekin ... führenden Wirkstoffkandidaten STR001 zur Erhaltung des Resthörvermögens ... wurde, bekannt. Für die umfassende Phase-II-Doppelblindstudie mit ... Frankreich angeworben. STR001 wird während der Operation ...
(Date:4/27/2016)... NORWALK, Conn. , April 27, 2016 /PRNewswire/ ... availability of its digital health technology platform, which ... services and programs into scalable digital products, Zillion ... mobile engagement and empower consumers to take control ... features face-to-face live video conferencing – including one-to-one, ...
(Date:4/27/2016)... NEW YORK , April 27, 2016 /PRNewswire/ ... OASM ), a developer of a new ... today announced positive overall survival results for Paclical/Apealea ... total of 789 patients with epithelial ovarian cancer. ... treatment groups: Paclical/Apealea in combination with carboplatin versus ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... May 02, 2016 , ... Dr. Jonathan Kulbersh of Carolina Facial Plastics isn’t surprised ... five on the list of “ 5 US Cities with the Highest Plastic Rates .” ... and Miami. The results were calculated using a survey by RealSelf and ...
(Date:5/2/2016)... ... May 02, 2016 , ... MedaCheck, a leading medication ... outcomes, has announced its partnership with GrandView Health Services. , With decades of ... counter and prescription drug pharmacy services to thousands of residents. Serving Indiana, Ohio, ...
(Date:5/2/2016)... ... May 02, 2016 , ... The Evolve Paddle Board Company- which specializes ... today the outcome of their partnership with Yoloha Yoga- producers of high quality cork ... , SUP yoga has seen a dramatic rise in popularity throughout the last few ...
(Date:5/2/2016)... ... May 02, 2016 , ... One of Hollywood’s best kept ... Dermatology Surgery & Laser Center, in Milford, Penn. “Patients with busy lives want noninvasive ... fat treated and go home or back to work without having to wear recovery ...
(Date:5/2/2016)... Worcester, MA and Shelton, CT (PRWEB) , ... May 02, 2016 ... ... Scott Krug, President and Owner of New England Low Vision and Blindness (NELV&B) ... location will add more flexibility and convenience for people with vision impairments to get ...
Breaking Medicine News(10 mins):